Respin, the health and wellness platform founded by actress Halle Berry, has announced it is launching its female longevity platform focussed on perimenopause and menopause.
Respin is a community-based platform where women can ask questions, engage in meaningful discussions, and build connections. The platform aims to provide a space where women navigating menopause and longevity can find empowerment through shared insights and collective support.
“I found out I was in perimenopause at 54 – abruptly, with no warning from my doctors. I was not prepared and did not know where to turn for support,” said Halle Berry.
“I was one of the millions of women who spend four to five years of their lives being misdiagnosed or not diagnosed at all. As a result, I’ve been driven towards what I now believe is the biggest respin of all – to break the stigma around menopause, sharing my journey and a newfound sense of empowerment.
“Menopause impacts over half the world’s population, and my goal is to inspire women to embrace this natural transition with the support they deserve – years before your first hot flash.
“At Respin, we’re now building what I wish I’d had access to—a resource for women in the midst of menopause, on the cusp of it in perimenopause, or preparing for it.
“We are focused on making this experience better for women, and that starts with being rooted in community, backed by science, and leveraging technology to scale. We’re redefining what it means to live a healthy life during your second act.
“The future of menopause is not a cure, it’s a journey. I strongly felt like the service I needed didn’t exist – so I realised we would have to build it ourselves. Women, regardless of whether or not they choose to engage with HRT or non-hormonal prescription offerings, need and deserve care that includes comprehensive holistic coaching, community support and access to trusted science, all under one roof, to guide them through their individualised journeys.”
Respin Health piloted an invite-only beta programme over the summer that served as the foundation for the personalised Respin Health service which is now available to the public.
Pilot results showed that in an eight-week period, 90 per cent of members had a directional improvement in symptoms, with 64 per cent of members experiencing a clinically significant improvement in symptoms as indicated by an overall.
A total of 40 per cent of the Respin Health pilot programme identified as women of colour. It is prevalent that menopause affects women of colour differently, and Respin Health has said it is uniquely positioned to track both interventions and outcomes.
Respin Health asks about race as one of many factors that go into an individual’s profile, so they can start to build actionable data to inform better recommendations over time in their real-world setting.
